Table 3.
Retention of patients, 50% responder rates Intention-to-treat analysis (ITT), and reasons for discontinuation over 1-year of treatment with 140 mg erenumab monthly.
| TIMEPOINTS | Month 3 | Month 6 | Month 9 | Month 12 |
|---|---|---|---|---|
| EPISODIC MIGRAINE (ITT analysis) | ||||
| Number of patients | 80 | 78 | 73 | 62 |
| ≥50% responders (%) | 44 (55%) | 43 (54%) | 41 (51%) | 41 (51%) |
| Discontinuation due to lack of efficacy | – | 2 | 4 | 4 |
| Discontinuation due to adverse effects | – | – | 1 | 1 |
| Discontinuation due to migraine remission | – | – | – | 6 |
| CHRONIC MIGRAINE (ITT analysis) | ||||
| Number of patients | 76 | 63 | 53 | 49 |
| ≥50% responders (%) | 31 (41%) | 34 (45%) | 40 (53%) | 31 (41%) |
| Discontinuation due to lack of efficacy | – | 9 | 10 | 4 |
| Discontinuation due to adverse effects | – | 4 | – | – |
| Discontinuation due to migraine remission | – | – | – | – |